Reports Q4 revenue $13.6M, consensus $13.41M. “The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak registrational program for bexobrutideg and strengthened our balance sheet to support execution across our pipeline,” said CEO Arthur Sands.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Outlines 2026 Goals and Pipeline Progress
- Nurix Therapeutics highlights key objectives, milestones
- Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
- Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients
- HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks